Report Detail

Pharma & Healthcare Global (United States, European Union and China) Meningococcal Conjugate Vaccine Market Research Report 2019-2025

  • RnM3379960
  • |
  • 06 May, 2019
  • |
  • Global
  • |
  • 115 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Meningococcal Conjugate Vaccine Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Menactra
      • 1.3.3 MENVEO
    • 1.4 Market Segment by Application
      • 1.4.1 Global Meningococcal Conjugate Vaccine Market Share by Application (2019-2025)
      • 1.4.2 Children
      • 1.4.3 Adults
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Meningococcal Conjugate Vaccine Market Size
      • 2.1.1 Global Meningococcal Conjugate Vaccine Revenue 2014-2025
      • 2.1.2 Global Meningococcal Conjugate Vaccine Sales 2014-2025
    • 2.2 Meningococcal Conjugate Vaccine Growth Rate by Regions
      • 2.2.1 Global Meningococcal Conjugate Vaccine Sales by Regions 2014-2019
      • 2.2.2 Global Meningococcal Conjugate Vaccine Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Meningococcal Conjugate Vaccine Sales by Manufacturers
      • 3.1.1 Meningococcal Conjugate Vaccine Sales by Manufacturers 2014-2019
      • 3.1.2 Meningococcal Conjugate Vaccine Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Meningococcal Conjugate Vaccine Revenue by Manufacturers (2014-2019)
      • 3.2.2 Meningococcal Conjugate Vaccine Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Meningococcal Conjugate Vaccine Market Concentration Ratio (CR5 and HHI)
    • 3.3 Meningococcal Conjugate Vaccine Price by Manufacturers
    • 3.4 Key Manufacturers Meningococcal Conjugate Vaccine Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Meningococcal Conjugate Vaccine Market
    • 3.6 Key Manufacturers Meningococcal Conjugate Vaccine Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Menactra Sales and Revenue (2014-2019)
      • 4.1.2 MENVEO Sales and Revenue (2014-2019)
    • 4.2 Global Meningococcal Conjugate Vaccine Sales Market Share by Type
    • 4.3 Global Meningococcal Conjugate Vaccine Revenue Market Share by Type
    • 4.4 Meningococcal Conjugate Vaccine Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Meningococcal Conjugate Vaccine Sales by Application

    6 United States

    • 6.1 United States Meningococcal Conjugate Vaccine Breakdown Data by Company
    • 6.2 United States Meningococcal Conjugate Vaccine Breakdown Data by Type
    • 6.3 United States Meningococcal Conjugate Vaccine Breakdown Data by Application

    7 European Union

    • 7.1 European Union Meningococcal Conjugate Vaccine Breakdown Data by Company
    • 7.2 European Union Meningococcal Conjugate Vaccine Breakdown Data by Type
    • 7.3 European Union Meningococcal Conjugate Vaccine Breakdown Data by Application

    8 China

    • 8.1 China Meningococcal Conjugate Vaccine Breakdown Data by Company
    • 8.2 China Meningococcal Conjugate Vaccine Breakdown Data by Type
    • 8.3 China Meningococcal Conjugate Vaccine Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Meningococcal Conjugate Vaccine Breakdown Data by Company
    • 9.2 Rest of World Meningococcal Conjugate Vaccine Breakdown Data by Type
    • 9.3 Rest of World Meningococcal Conjugate Vaccine Breakdown Data by Application
    • 9.4 Rest of World Meningococcal Conjugate Vaccine Breakdown Data by Countries
      • 9.4.1 Rest of World Meningococcal Conjugate Vaccine Sales by Countries
      • 9.4.2 Rest of World Meningococcal Conjugate Vaccine Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 GlaxoSmithKline
      • 10.1.1 GlaxoSmithKline Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Meningococcal Conjugate Vaccine
      • 10.1.4 Meningococcal Conjugate Vaccine Product Introduction
      • 10.1.5 GlaxoSmithKline Recent Development
    • 10.2 Pfizer
      • 10.2.1 Pfizer Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Meningococcal Conjugate Vaccine
      • 10.2.4 Meningococcal Conjugate Vaccine Product Introduction
      • 10.2.5 Pfizer Recent Development
    • 10.3 Sanofi
      • 10.3.1 Sanofi Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Meningococcal Conjugate Vaccine
      • 10.3.4 Meningococcal Conjugate Vaccine Product Introduction
      • 10.3.5 Sanofi Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Meningococcal Conjugate Vaccine Sales Channels
      • 11.2.2 Meningococcal Conjugate Vaccine Distributors
    • 11.3 Meningococcal Conjugate Vaccine Customers

    12 Market Forecast

    • 12.1 Global Meningococcal Conjugate Vaccine Sales and Revenue Forecast 2019-2025
    • 12.2 Global Meningococcal Conjugate Vaccine Sales Forecast by Type
    • 12.3 Global Meningococcal Conjugate Vaccine Sales Forecast by Application
    • 12.4 Meningococcal Conjugate Vaccine Forecast by Regions
      • 12.4.1 Global Meningococcal Conjugate Vaccine Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Meningococcal Conjugate Vaccine Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Meningococcal Conjugate Vaccine is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Meningococcal Conjugate Vaccine.

      This report studies the global market size of Meningococcal Conjugate Vaccine, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Meningococcal Conjugate Vaccine sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      GlaxoSmithKline
      Pfizer
      Sanofi
      ...

      Market Segment by Product Type
      Menactra
      MENVEO

      Market Segment by Application
      Children
      Adults

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Meningococcal Conjugate Vaccine status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Meningococcal Conjugate Vaccine manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Meningococcal Conjugate Vaccine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025


      Summary:
      Get latest Market Research Reports on Meningococcal Conjugate Vaccine . Industry analysis & Market Report on Meningococcal Conjugate Vaccine is a syndicated market report, published as Global (United States, European Union and China) Meningococcal Conjugate Vaccine Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Meningococcal Conjugate Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,280.00
      $4,920.00
      $6,560.00
      2,350.34
      3,525.50
      4,700.67
      2,714.77
      4,072.16
      5,429.55
      350,133.44
      525,200.16
      700,266.88
      241,217.76
      361,826.64
      482,435.52
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report